# Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Page: https://stenobird.com/podcast/the-imid-forum-981476/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa
Text version: https://stenobird.com/podcast/the-imid-forum-981476/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa.md
Podcast: [The IMID Forum](https://stenobird.com/podcast/the-imid-forum-981476)
Published: 2025-12-04T09:00:03+00:00
Episode link: https://soundcloud.com/imidforum/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa
Audio file: https://feeds.soundcloud.com/stream/2222625149-imidforum-discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa
Duration seconds: 1247

## Resource

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-imid-forum-981476/episodes/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-imid-forum-981476/discussing-psa-uveitis-risk-and-treatment-sequencing-outcomes-in-axspa-and-psa.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.